The Heidelberg Engineering ANTERION Anterior Segment Cornea and IOL Precision and Agreement Study

April 26, 2024 updated by: Heidelberg Engineering GmbH
This is a prospective clinical study that will be conducted at one clinical site located in the United States to assess anterior segment parameters with the ANTERION

Study Overview

Status

Completed

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

176

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New York
      • New York, New York, United States, 10036
        • State University of New York College of Optometry

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

Eyes with normal anterior segment and crystalline lens; eyes with cataract of grade 1.5 or higher; eyes with abnormal corneal shape; eyes with status post-keratorefractive surgery and eyes without a crystalline lens

Description

Inclusion Criteria:

  1. Age 22 years or older
  2. Able and willing to undergo the test procedures, sign informed consent, and follow instructions
  3. Able to fixate
  4. With the following eye pathology status for the individual eye population:

    • A. Eye with normal anterior segment and crystalline lens
    • B. Eye with a cataract of grade 1.5 or higher
    • C. Eye with abnormal corneal shape
    • D. Eye with status post-keratorefractive surgery
    • E. Eye without a crystalline lens

Exclusion Criteria:

  1. Subjects which were enrolled in the B-2018-1 clinical study
  2. Active infection or inflammation in the study eye
  3. Insufficient tear film or corneal reflex
  4. Physical inability to be properly positioned at the study devices or eye exam equipment
  5. Rigid contact lens wear 2 weeks prior to imaging
  6. Soft lenses worn within one hour prior to imaging
  7. With the following eye pathology status for the individual eye population:

    • A. Eye meets eligibility criteria for eye populations B, C, D or E
    • B. Eye meets eligibility criteria for eye populations C,D or E
    • C. Eye meets eligibility criteria for eye populations D or E
    • E. Eye with abnormal corneal shape (except status post-keratorefractive surgery)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Eye with normal Anterior Segment
3 repeat measurements on each of the 3 investigational and reference devices
3 repeat measurements performed with two of the ANTERION acquisition types and 3 repeat measurements performed with 2 acquisition types of the references devices
Eye with cataract
3 repeat measurements on each of the 3 investigational and reference devices
3 repeat measurements performed with two of the ANTERION acquisition types and 3 repeat measurements performed with 2 acquisition types of the references devices
Eye with corneal abnormality
3 repeat measurements on each of the 3 investigational and reference devices
3 repeat measurements performed with two of the ANTERION acquisition types and 3 repeat measurements performed with 2 acquisition types of the references devices
Eye with status post-keratorefractive surgery
3 repeat measurements on each of the 3 investigational and reference devices
3 repeat measurements performed with two of the ANTERION acquisition types and 3 repeat measurements performed with 2 acquisition types of the references devices
Eye without a crystalline lens
3 repeat measurements on each of the 3 investigational and reference devices
3 repeat measurements performed with two of the ANTERION acquisition types and 3 repeat measurements performed with 2 acquisition types of the references devices

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Precision and Agreement 1
Time Frame: 1 day
Reproducibility, repeatability and agreement of Anterior Corneal Topography parameters (3mm ring) of ANTERION and the reference device
1 day
Precision and Agreement 2
Time Frame: 1 day
Reproducibility, repeatability and agreement of Anterior Corneal Topography parameters (6mm zone) of ANTERION and the reference device
1 day
Precision and Agreement 3
Time Frame: 1 day
Reproducibility, repeatability and agreement of Posterior Corneal Topography parameters (3mm ring) of ANTERION and the reference device
1 day
Precision and Agreement 4
Time Frame: 1 day
Reproducibility, repeatability and agreement of Posterior Corneal Topography parameters (6mm zone) of ANTERION and the reference device
1 day
Precision and Agreement 5
Time Frame: 1 day
Reproducibility, repeatability and agreement of Cornea Thickness (µm) of ANTERION and the reference device
1 day
Precision and Agreement 6
Time Frame: 1 day
Reproducibility, repeatability and agreement of Lens Thickness, ACD, Pupil Diameter, White-to-White, Axial Length (mm) of ANTERION and the reference device
1 day
Precision and Agreement 7
Time Frame: 1 day
Reproducibility, repeatability and agreement of Anterior Chamber Volume (mm^3) of ANTERION and the reference device
1 day

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Adverse Events Rate
Time Frame: 1 day
Adverse events found during the clinical study
1 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Mitchell Dul, State University of New York College of Optometry

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 11, 2019

Primary Completion (Actual)

October 30, 2023

Study Completion (Actual)

December 30, 2023

Study Registration Dates

First Submitted

October 11, 2019

First Submitted That Met QC Criteria

October 15, 2019

First Posted (Actual)

October 17, 2019

Study Record Updates

Last Update Posted (Actual)

April 30, 2024

Last Update Submitted That Met QC Criteria

April 26, 2024

Last Verified

April 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • B-2018-5

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe